Bifogade filer
Interim Report Q3 2024
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Magle Group (publ) reports strong Q3 2024 performance, with sales growth and strategic mergers positioning the company for future market expansion.
Q3 2024 KEY INDICATORS
Net sales amounted to 64.6 MSEK (36.3).
EBITDA equalled 26.5 MSEK (4.8).
Operating profit (EBIT) is 13.7 MSEK (1.5)
Profit after tax amounted to 9.6 MSEK (0.5)
JAN-SEP 2024 KEY INDICATORS
Net sales amounted to 148.8 MSEK (113.1).
EBITDA equalled 38.8 MSEK (21.8).
Operating profit (EBIT) is 19.2 MSEK (12.1)
Profit after tax amounted to 12.7 MSEK (8.1)
“As we close the third quarter of 2024, I am pleased to report strong progress for Magle Group. We have successfully completed the merger with PK Chemical A/S and are nearing completion with Amniotics AB. These strategic acquisitions bring valuable technologies that strengthen our mission to deliver innovative healthcare solutions. This quarter's results were positively impacted by the purchase price allocation (PPA) under IFRS, contributing a one-off, extraordinary income. Excluding the PPA adjustment, our underlying performance remains solid, with revenue for the quarter reaching 69.9 MSEK, up from 40.59 MSEK last year. Looking ahead, we remain focused on integrating our new businesses, driving growth, and achieving cost synergies. I am confident that our efforts will position us for sustained success.” said Justin Pierce, CEO.